Akihiro Takeshita
Overview
Explore the profile of Akihiro Takeshita including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
726
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tamai Y, Ohto H, Yasuda H, Takeshita A, Fujii N, Ogo H, et al.
Transfusion
. 2021 Jul;
61(9):2718-2726.
PMID: 34287925
Background: Anti-M is frequently observed as a naturally occurring antibody of little clinical significance. Naturally occurring anti-M is often found in children although the specific triggers of production, persistence, and...
2.
Tanaka A, Yokohama A, Fujiwara S, Fujii Y, Kaneko M, Ueda Y, et al.
Vox Sang
. 2021 Feb;
116(7):785-792.
PMID: 33529383
Background: Transfusion-associated circulatory overload (TACO) is an adverse reaction associated with a high risk of mortality. The actual incidence of TACO and hypertension associated with transfusion in Japan is unknown....
3.
Furumaki H, Takeshita A, Ohto H, Yamada C, Fujihara H, Ishizuka K, et al.
Vox Sang
. 2020 Dec;
116(6):725-734.
PMID: 33314130
Background And Objectives: Anti-CD38 monoclonal antibodies, including daratumumab and isatuximab, often interfere with pretransfusion testing. Dithiothreitol (DTT) treatment of red blood cells (RBCs) negates this interference. However, the optimum DTT...
4.
Takeshita A, Watanabe H, Yamada C, Sekaran Nadarajan V, Permpikul P, Sinkitjasub A, et al.
Transfus Apher Sci
. 2020 Nov;
59(5):102944.
PMID: 33228922
As an East-Asian international study, we evaluated erythrocyte alloimmunity by gender and history of transfusion or pregnancy. In total, data from more than 1,826,000 patients were analyzed, from whom 26,170...
5.
Minamiguchi H, Fujita H, Atsuta Y, Asou N, Sakura T, Ueda Y, et al.
Ann Hematol
. 2020 Sep;
99(12):2787-2800.
PMID: 32879992
Significant advancements have been achieved with regard to the outcomes of acute promyelocytic leukemia (APL) patients through the introduction of all-trans retinoic acid; however, early hemorrhagic death and differentiation syndrome...
6.
Yokohama A, Okuyama Y, Ueda Y, Itoh M, Fujiwara S, Hasegawa Y, et al.
Int J Hematol
. 2020 Jul;
112(4):535-543.
PMID: 32683598
A hemoglobin (Hb) threshold level of 7 g/dL has been proposed for red blood cell (RBC) transfusion in patients with chronic anemia in the Japanese guideline since 2005. However, Hb...
7.
Takeshita A, Asou N, Atsuta Y, Furumaki H, Sakura T, Ueda Y, et al.
Cancers (Basel)
. 2020 Jun;
12(6).
PMID: 32492981
Background: After long-term analysis of the JALSG-APL204 study we recently reported that maintenance therapy with tamibarotene was more effective than all-trans retinoic acid (ATRA) by reducing relapse in APL patients....
8.
Fujiwara S, Ikeda K, Kino S, Tanaka A, Hasegawa Y, Fujino K, et al.
Int J Hematol
. 2020 Mar;
111(6):833-839.
PMID: 32172447
In the Japan Marrow Donor Program (JMDP), autologous blood is collected from most unrelated bone marrow (BM) donors. We retrospectively evaluated 5772 donors who underwent BM harvest between 2010 and...
9.
Yamada C, Takeshita A, Ohto H, Ishimaru K, Kawabata K, Nomaguchi Y, et al.
Vox Sang
. 2020 Mar;
115(5):456-465.
PMID: 32124460
Background And Objectives: It is sometimes difficult to obtain antigen-negative red blood cells (RBCs) for patients with antibodies against RBCs. However, the frequency and severity of the adverse reactions have...
10.
Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, et al.
Int J Hematol
. 2019 Feb;
109(4):418-425.
PMID: 30725360
Given the poor prognosis of patients with relapsed/refractory acute myeloid leukemia (AML), better therapy is needed. Fludarabine enhances the efficacy of Ara-C (cytarabine) by increasing intracellular Ara-C-triphosphate. The FLAG (fludarabine,...